Compare Adaptive Biotechnologies Corp (ADPT) vs Bumble Inc (BMBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bumble Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.99 (market cap $4.04B), while Bumble Inc trades at $2.64 (market cap $366.87M). The key difference: Adaptive Biotechnologies Corp is far larger — about 11× Bumble Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BMBL | |
|---|---|---|
Market Cap | $4.04B | $366.87M |
Sector | Health | Technology |
52-Week High | $25.45 | $7.17 |
52-Week Low | $12.30 | $2.70 |
Enterprise Value | $4.10B | $672.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
BMBL trades at $2.73, down 3.53% on the day, with a bearish technical outlook. The company reported a Q2 2026 earnings miss and negative net income margin of -57.96%, though revenue of $965.66M in 2025 shows scale. Recent news highlights a major shift in its women-first messaging policy to boost engagement amid slowing growth and exploration of a potential sale.
The outlook is challenged by persistent losses and declining paying users, but a low P/S of 0.38 offers valuation appeal. Risks include execution of product changes and intense competition. Analysts are mostly neutral with a $3.62 price target, suggesting cautious optimism if turnaround efforts succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →
